

From: Caudwell, Kerry M. (CDC/OD/OCS)
Sent: Tue, 25 May 2021 20:49:56 +0000
To: Berger, Sherri (CDC/OCOO/OD); Brown, Tiffany J. (CDC/OCOO/OSSAM/OD)
Cc: CDC Reports (CDC)
Subject: FOR REVIEW: CDC Cabinet Secretary Weekly Report for May 25 - updated template
Attachments: Template_Agency Weekly Report_5_24_21.docx, CDC Cabinet Secretary Weekly Report for May 25, 2021 v2.docx
Importance: High

Hi Sherri and Tiffany:

Action Needed: Attached, for your review, is CDC's input for the Cabinet Secretary Weekly Report that is due to HHS COB today.

The attachment reflects the template updates that were received from HHS last night (see email below and attachment). Revisions included:

(b)(5)

Please let me know if you have any questions or comments.

Thanks,
Kerry

From: Briskin, Perrie (HHS/OS) <Perrie.Briskin@hhs.gov>
Sent: Monday, May 24, 2021 5:38:29 PM
To: Cochran, Norris (HHS/ASFR) <norris.cochran@hhs.gov>; Chang, Jooyeun (ACF) <Jooyeun.Chang@acf.hhs.gov>; Barkoff, Alison (ACL) <Alison.Barkoff@acl.hhs.gov>; Meyers, David (AHRQ/IOD) Deputy Director <David.Meyers@ahrq.hhs.gov>; Richter, Elizabeth (CMS/CM) <elizabeth.richter@cms.hhs.gov>; Espinosa, Diana (HRSA) <DEspinosa@hrsa.gov>; Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Coderre, Tom (SAMHSA/OPPI) <Tom.Coderre@samhsa.hhs.gov>;

Seshasai, Karuna (HHS/IOS) <Karuna.Seshasai@hhs.gov>; Sullivan, Rose (HHS/ASL) <Rose.Sullivan@hhs.gov>; Bratcher-Bowman, Nikki (OS/ASPR/IO) <nikki.bratcherbowman@hhs.gov>; Lovenheim, Sarah (HHS/ASPA) <Sarah.Lovenheim@hhs.gov>; Frohboese, Robinsue (HHS/OCR) <Robinsue.Frohboese@HHS.GOV>; Barry, Daniel J (HHS/OGC) <daniel.barry@hhs.gov>; Grimm, Christi A (OIG/IO) <Christi.Grimm@oig.hhs.gov>; Figueroa, Marvin (HHS/IEA) <Marvin.Figueroa@hhs.gov>; Pace, Loyce (HHS/OS/OGA) <Loyce.Pace@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Woodcock, Janet (FDA/CDER) <Janet.Woodcock@fda.hhs.gov>; Fowler, Elizabeth A. (IHS/OKC/AO) <Elizabeth.Fowler@ihs.gov>; Haffajee, Rebecca (HHS/ASPE) <Rebecca.Haffajee@hhs.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Campbell, Cheryl (OS/ASA) <Cheryl.Campbell@hhs.gov>; Briskin, Perrie (HHS/OS) <Perrie.Briskin@hhs.gov>

Cc: Handerhan, Larry (ACF) <Larry.Handerhan@acf.hhs.gov>; Wright, Natasha (ACF) <Natasha.Wright@acf.hhs.gov>; Klocinski, Jennifer (ACL) <Jennifer.Klocinski@acl.hhs.gov>; Nicholls, Richard (ACL) <Richard.Nicholls@acl.hhs.gov>; Perry, Wendy (AHRQ/OD) <Wendy.Perry@ahrq.hhs.gov>; Bellios, Toula (CMS/OSPR) <Toula.Bellios@cms.hhs.gov>; Wu, Jeff (CMS/CCIIO) <Jeff.Wu@cms.hhs.gov>; Martino, Maria (CMS/OL) <Maria.Martino@cms.hhs.gov>; Goodman, Michelle (HRSA) <MGoodman@hrsa.gov>; Grossman, Jordan (HRSA) <JGrossman@hrsa.gov>; Patel, Nisha (HRSA) <NPatel@hrsa.gov>; Heppner, Eliza (HRSA) <ehheppner@hrsa.gov>; ESHHSReportsTeam@nih.gov <ESHHSReportsTeam@nih.gov>; Tabak, Lawrence (NIH/OD) [E] <Lawrence.Tabak@nih.gov>; Allen-Gifford, Patrice (NIH/OD) [E] <patrice.allen-gifford@nih.gov>; Gallardo, Daniel (SAMHSA/OAS) <Daniel.Gallardo@samhsa.hhs.gov>; Chessen, Sonia (SAMHSA/OAS) <Sonia.Chessen@samhsa.hhs.gov>; Gallardo, Daniel (SAMHSA/OAS) <Daniel.Gallardo@samhsa.hhs.gov>; Robinson, Wilma (HHS/IOS) <Wilma.Robinson@hhs.gov>; Tatem, Anne (HHS/OS/ASL) <Anne.Tatem@hhs.gov>; Espinosa, Kimberly (HHS/ASL) <Kimberly.Espinosa@hhs.gov>; Hild, Jeff (HHS/ASL) <Jeff.Hild@hhs.gov>; Perry, Ijeoma (OS/ASPR/EMMO) <Ijeoma.Perry@hhs.gov>; Wulff, Kacey (OS/ASPR/IO) <Kacey.Wulff@hhs.gov>; Alvarez, Kathryn (OS/IOS) <Kathryn.Alvarez@hhs.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Lynk, Beth (HHS/ASPA) <Florence.Lynk@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Peck, Joshua (HHS/ASPA) <Joshua.Peck@hhs.gov>; Weber, Mark (HHS/ASPA) <Mark.Weber@hhs.gov>; Henderson, Harold (HHS/OCR) <Harold.Henderson@hhs.gov>; Durso, Laura (HHS/OCR) <Laura.Durso@hhs.gov>; Akpa, Stephanie (HHS/OCR) <Stephanie.Akpa@hhs.gov>; Tobias, Constance (HHS/DAB) <Constance.Tobias@hhs.gov>; Scott, Katherine (OS/DAB) <Katherine.Scott@hhs.gov>; Howard, Lemuel (OS/DAB) <Lemuel.Howard@hhs.gov>; Montgomery, Meredith (HHS/DAB) <Meredith.Montgomery@hhs.gov>; Barclay, Lisa (HHS/OGC) <Lisa.Barclay@hhs.gov>; Rodriguez, Paul (HHS/OGC) <PaulR.Rodriguez@hhs.gov>; McGarey, Barbara (HHS/OGC) <Barbara.McGarey@hhs.gov>; Keveney, Sean (HHS/OGC) <Sean.Keveney@hhs.gov>; Allen, McArthur (HHS/OMHA) <Mcarthur.Allen@hhs.gov>; Shelton, Carrie A (HHS/OS/OMHA) <Carrie.Shelton@HHS.GOV>; McGuinness, Laura (OS/OMHA) <Laura.McGuinness@hhs.gov>; Tripathi, Micky (OS/ONC) <Micky.Tripathi@hhs.gov>; Swain, Matthew (OS/ONC) <Matthew.Swain@hhs.gov>; Kost, Michelle (OS/ONC) <Michelle.Kost@hhs.gov>; Stevens, Lee (OS/IEA) <Lee.Stevens@hhs.gov>; Mciff, Colin (HHS/OS/OGA) <Colin.Mciff@hhs.gov>; Psaki, Stephanie (HHS/OS/OGA) <Stephanie.Psaki@hhs.gov>; Schaeffer, Alison (HHS/OS/OGA) <Alison.Schaeffer@hhs.gov>; LaHood, Natalie (OS/OGA) <Natalie.Lahood@hhs.gov>; Tcholakian, Karoun (HHS/OS/OGA) <Karoun.Tcholakian@hhs.gov>; Caudwell, Kerry M. (CDC/OD/OCS) <cli9@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Brown, Tiffany J. (CDC/OCOO/OSSAM/OD) <iji3@cdc.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Tobias, Lindsay (FDA/OC) <Lindsay.Tobias@fda.hhs.gov>; Church, Ann M. (IHS/HQ) <Ann.Church@ihs.gov>; Carr, Elizabeth (IHS/HQ) <Elizabeth.Carr@ihs.gov>; Kim, Shalley (OS/ASA) <Shalley.Kim@hhs.gov>; Duncan, Blair (OS/ASA) <Blair.Duncan@hhs.gov>; Swenson-O'Brien, Alicia (OS/ASPE) <Alicia.Swenson-O'Brien@hhs.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Handley, Elisabeth

(OS/OASH/ORI) <Elisabeth.Handley@hhs.gov>; Oh, Kathy J. (CMS/OHC) <Kathy.Oh@cms.hhs.gov>; Fisher, Megan (HHS/OASH) <Megan.Fisher@hhs.gov>; Pryor, Rachel (HHS/OS/IOS) <Rachel.Pryor@hhs.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Villanueva, Josie (OS/IOS) <Josie.Villanueva@hhs.gov>; Rainer, Melanie Fontes (OS/IOS) <Melanie.Rainer@hhs.gov>; Cha, Stephen (HHS/IOS) <Stephen.Cha@hhs.gov>; Lopez, Steven (HHS/OS/IOS) <Steven.Lopez@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>; Reid, Anne (OS/IOS) <Anne.Reid@hhs.gov>; Mccluskie, Sean (HHS/IOS) <Sean.Mccluskie@hhs.gov>; Harris, James (HHS/Partnership Center) <James.Harris3@hhs.gov>; Orozco, Esmeralda (HHS/IOS) <Esmeralda.Orozco@hhs.gov>; Palafox, Cynthia (HHS/IOS) <Cynthia.Palafox@hhs.gov>

Subject: Weekly Cabinet Affairs Report - New Template and Guidance

Hello,

We have received the below guidance and update template attached from Cabinet Affairs. The most significant updates are to additional sections in the Appendix.

As always, please submit your division's reports to me and Clare by COB tomorrow, Tuesday.

Also, as an FYI, the counselors are now doing a closer review of divisions' weekly reports before the final report goes to Cabinet Affairs.

Thank you. Please let me and Clare know if you have any questions.

Best,
Perrie

5/24 Weekly Cabinet Affairs Report Guidance

Main report sections:

- **Audience reminder:** Please remember that you are writing for an audience that is not steeped in the policy expertise or acronyms of your agency. As such, when you include an item please make sure your description is succinct, includes enough context to be understood by a layperson, and answers the inherent question of why this item is important.
- **Setbacks/Obstacles:** The accomplishments are important, and it's also important for White House offices to be aware of setbacks and obstacles. Please include these, and where something is more sensitive you're welcome to call or email our team to discuss instead.

Appendix section:

- **4-week look-ahead:** In the Appendix, please list items covering the previous week and the look ahead for 4 weeks out.
- If something is tentative or the date is TBD, please include and note accordingly.
- If something was scheduled and changes or gets cancelled, please let us know directly or include that update in the next week's report.
- **Travel template for Cabinet members:** For Cabinet Member travel going forward, please provide the details for each expected trip at least 4 weeks out in the following format:
- **Date – Location(s):** Topline event description, including type of event (roundtable, tour, etc.), participants, and topic (ARP, AJP, AFP, etc.)

- *Example: **May 31st** – Ford Plant in Dearborn, Michigan*: Secretary Granholm will participate in a roundtable with Ford executives and United Auto Workers (UAW) members to discuss electric vehicles and how both AJP and AFP will support U.S. competitiveness, create good-paying jobs and help us reach climate goals. Senators Gary Peters (D-MI) and Debbie Stabenow (D-MI) and Governor Gretchen Whitmer (D-MI) have been invited. We expect to notice this event on May 28th.
- New sections for funding and grant announcements: At the request of the Domestic Policy Council, we have added new separate sections for you to list grant notices (NOFA/NOFOs) and funding announcements.
- For all Appendix items, please indicate where an engagement is specific to ARP, AJP, AFP, or other priorities.

Date Formatting: Please include ordinal indicators (rd/th/nd/st) after numbers (no superscript), and do not include year unless referring to an earlier/future year that requires clarification.

Perrie Briskin
Senior Advisor to the Chief of Staff
U.S. Department of Health and Human Services
Cell: (b)(6)
Perrie.Briskin@hhs.gov

Weekly Report - Agency

Submitted on MM/DD/YYYY

Weekly reports should be Arial, size 14 font; additional information, if necessary, may be included in the appendix

WEEKLY REPORT

Month DD, YYYY

MEMORANDUM FOR THE CABINET SECRETARY

FROM: [FIRST LAST], [DEPARTMENT], [PHONE NUMBER]

SUBJECT: [Agency] Weekly Report | Week ending (Month DD, YYYY)

AMERICAN RESCUE PLAN (ARP) / AMERICAN JOBS PLAN (AJP) / ECONOMY

The American Rescue Plan and American Jobs Plan are cross-cutting priorities among many agencies. Please list in bullet form how your agency is working to implement ARP, to bring AJP across the finish line, as well as broader efforts supporting the economy.

In the below sub-sections, be sure to include significant progress and/or setbacks towards high priority agency goals, progress on implementing Executive Orders / policy agenda, and principal-level activity.

Note: Please order bullets by priority in all sections

Sections are:

- **Significant activity for consideration to raise to the attention of POTUS:**
 - 0-3 bullets as needed
 - Please begin each point with a short 2-5 word **bolded descriptive subject line**
 - Ex: **“State and Local Funding:** On May 10th, the Department of the Treasury launched the portal to process applications for the \$350 billion State and Local Fiscal Recovery Fund. Over 1,200 entities have successfully completed their submissions.

Briefing Memo - Subject

Printed on MM/DD/YYYY

- Do NOT bold any other words or phrases in the bullet outside of the sections, sub-sections, and subject lines. Do NOT bold agency names.
- Make sure all bullets in this section can be read as standalone bullets without needing additional context.
- Include date of action, hard numbers and data wherever possible
 - Example: “**COVID-19 Home Tests**: On February 1st, Department of Defense (DOD) and Department of Health and Human Services (HHS) awarded \$231.8 million to increase onshore production capacity of the Ellume COVID-19 Home Test for the United States, improving production capacity to 640,000 tests per day by December 2021.”
- Include bullets only with concrete actions, announcements, meetings, etc. Avoid generalities as much as possible.
 - Ex: Do NOT say “[Agency] continued to implement COVID-19 work safety plan.”
- Do not use acronyms. Spell out a name then put acronym in parentheses.
 - Ex: “Federal Emergency Management Agency (FEMA)”
- Do not include year and do not superscript dates.
 - Ex: “On February 1st” - (not “On February 1st”)
- **Past Week Accomplishments and Setbacks/Obstacles:**
 - 0-5 bullets as needed
 - Remove sub-section if leaving blank. Put “N/A” if zero entries for the entire section (i.e. no points for anything in ARP)
- **Requests for White House Collaboration:**
 - 0-1 bullets as needed
- **Next Week – Upcoming Events / Tasks / Developments:**
 - 0-5 bullets as needed

COVID-19

Briefing Memo - Subject

Printed on MM/DD/YYYY

Tackling COVID-19 is a cross-cutting priority among many agencies. Please list in bullet form how your agency is working to fulfill the administration's mandate in addressing the pandemic.

In the below sub-sections, be sure to include significant progress and/or setbacks towards high priority agency goals, progress on implementing Executive Orders / policy agenda, and principal-level activity.

Same sections:

- **Significant activity for consideration to raise to the attention of POTUS:**
 - 0-3 bullets as needed
- **Past Week Accomplishments and Setbacks/Obstacles:**
 - 0-5 bullets as needed
- **Requests for White House Collaboration:**
 - 0-1 bullets as needed
- **Next Week – Upcoming Events / Tasks / Developments:**
 - 0-5 bullets as needed

CLIMATE

Addressing the climate crisis is a cross-cutting priority among many agencies. Please list in bullet form how your agency is working to advance the goals of the administration's climate agenda.

In the below sub-sections, be sure to include significant progress and/or setbacks towards high priority agency goals, progress on implementing Executive Orders / policy agenda, and principal-level activity.

Same sections:

- **Significant activity for consideration to raise to the attention of POTUS:**
 - 0-3 bullets as needed
- **Past Week Accomplishments and Setbacks/Obstacles:**
 - 0-5 bullets as needed

Briefing Memo - Subject

Printed on MM/DD/YYYY

- **Requests for White House Collaboration:**
 - 0-1 bullets as needed

- **Next Week – Upcoming Events / Tasks / Developments:**
 - 0-5 bullets as needed

RACIAL EQUITY

Racial Equity is a priority for all agencies. Please list in bullet form how your agency is working to advance the administration's goals and ensuring that racial equity is deeply rooted in all engagements and efforts.

In the below sub-sections, be sure to include significant progress and/or setbacks towards high priority agency goals, progress on implementing Executive Orders / policy agenda, and principal-level activity.

Same sections:

- **Significant activity for consideration to raise to the attention of POTUS:**
 - 0-3 bullets as needed

- **Past Week Accomplishments and Setbacks/Obstacles:**
 - 0-5 bullets as needed

- **Requests for White House Collaboration:**
 - 0-1 bullets as needed

- **Next Week – Upcoming Events / Tasks / Developments:**
 - 0-5 bullets as needed

SIGNIFICANT EXECUTIVE ORDER (EO) & AGENCY ACTIVITY

Please list any significant agency activity, including activities related to executive orders, important agency initiatives, announcements, and actions that do not fall into the above priority buckets. Please pay special attention to actions which may have significant interest in particular geographic regions.

Briefing Memo - Subject

Printed on MM/DD/YYYY

If you have an item that fits into more than one of the issue areas above, you're also welcome to include it in this section.

In the below sub-sections, as needed, you may include significant progress and/or setbacks towards additional high priority agency goals, progress on implementing Executive Orders / policy agenda, and principal-level activity.

Sections are:

- **Significant activity for consideration to raise to the attention of POTUS:**
 - 0-3 bullets as needed

- **Past Week Accomplishments and Setbacks/Obstacles:**
 - 0-5 bullets as needed
 - Remove sub-section if leaving blank. Put "N/A" if zero entries for the entire section (i.e. no points for anything in ARP)
 - Order bullets by priority in all sections

- **Requests for White House Collaboration:**
 - 0-1 bullets as needed

- **Next Week – Upcoming Events / Tasks / Developments:**
 - 0-5 bullets as needed

APPENDIX

In the below sub-sections please be as comprehensive and detailed as possible. Please list details for the previous week and a look-ahead at least 4 weeks out in all sections where possible, and particularly for Travel, Speeches, and Media appearances. And where applicable, please indicate if an engagement was specific to ARP, AJP, AFP, or another priority.

Sections are:

- **Week ahead messaging:**
 - Please include 3-5 bullet points about what your agency's top messaging priorities are for the next week

Briefing Memo - Subject

Printed on MM/DD/YYYY

- Please also flag any upcoming activity you think White House Comms should be aware of

- **Travel:**
 - List travel in the following format:
 - **Date** – Location(s): Topline event description, including type of event (roundtable, tour, etc.)
 - Key attendees: Members of Congress, key local elected officials and/or business/non-profit/community/faith leaders
 - When event will be noticed publicly
 - Please label if supporting AJP, ARP, and/or AFP, or if another priority
 - *Example: **May 31st** – Ford Plant in Dearborn, Michigan: Secretary Granholm will participate in a roundtable with Ford executives and United Auto Workers (UAW) members to discuss electric vehicles and how both AJP and AFP will support U.S. competitiveness, create good-paying jobs and help us reach climate goals. Senators Gary Peters (D-MI) and Debbie Stabenow (D-MI) and Governor Gretchen Whitmer (D-MI) have been invited. We expect to notice this event on May 28th.*

 - Recent (previous week) and upcoming (4 weeks minimum)
 - Include TBD date and tentative travel as well, indicating so

- **Speeches:**
 - Recent (previous week) and upcoming (4 weeks minimum)

- **Media:**
 - Principal-level interviews
 - Recent (previous week) and upcoming (4 weeks minimum)

- **Principal level meetings or calls with Governors, Mayors, or other elected officials of note:**
 - Include any relevant meetings you would like to flag for White House Intergovernmental Affairs. These will vary by agency

Briefing Memo - Subject

Printed on MM/DD/YYYY

- and could include but are not limited to Attorneys General, Education Commissioners, Health Secretaries, etc.
 - Recent (previous week) and upcoming (4 weeks minimum)
 - Include purpose, agenda/topics covered
- **Noteworthy public engagement:**
 - Noteworthy public engagement could include but is not limited to meetings with unions, business leaders, faith and community leaders, constituency groups, etc.
 - Principal-level engagement
 - Recent (previous week) and upcoming (4 weeks minimum)
- **Principal level meetings or calls with Members of Congress:**
 - Recent (previous week) and upcoming (4 weeks minimum)
 - Include purpose, agenda/topics covered
- **Noteworthy inquiries from Congressional committees or Members of Congress; scheduled testimony by Secretary or Deputy Secretary:**
 - These should be letters, requests for briefings, meetings, and hearings.
- **Noteworthy rulemaking in the Federal Register:**
 - Recent (previous week) and upcoming anticipated
- **Funding Announcements:**
 - Recent (previous week) and upcoming (4 weeks minimum)
- **Grant Notices (NOFA/NOFOs):**
 - Recent (previous week) and upcoming (4 weeks minimum)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)
Sent: Thu, 27 May 2021 14:19:06 +0000
To: Levine, Rachel (HHS/OASH); O'Connell, Dawn (HHS/IOS)
Cc: Boateng, Sarah (HHS/OASH); Sams, Ian (HHS/ASPA); Broido, Tara (HHS/OASH); Tierney, Julia (FDA/CBER); Beckman, Adam (HHS/OASH); Phillips, Alexandria (HHS/OASH); Berger, Sherri (CDC/OCOO/OD); Caccomo, Stephanie (FDA/OC); Walensky, Rochelle (CDC/OD)
Subject: Myocarditis Materials
Attachments: Web Content-Myocarditis-Clean.docx, Myocarditis Email to Clinicians.docx, Myocarditis Clinical Considerations.docx, Reactive on Myocarditis and Tough QA_Clean.docx

Dr. Levine, Dawn,

Attached are the pieces of the myocarditis content that are still in final review at CDC.

They include:

- Web content for consumers
- Email to clinicians
- Clinical considerations (web content)
- Reactive media statement and tough Q/A

Please let us know if you have additional questions or concerns.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 9:27 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER)

<Julia.Tierney@fda.hhs.gov>

Subject: RE: HAN

Good morning –

I believe the email below is still the current plan. As a reminder, both the ASH and Dawn would like to see the draft messages before we finalize/distribute. And, we should do the SHO outreach right beforehand.

Thanks,
Sherri

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>

Sent: Wednesday, May 26, 2021 6:08 PM

To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>

Subject: RE: HAN

Dr. Levine,

We are still discussing the strategy on this topic. However, after discussions internally and with FDA, we will likely (b)(5)

(b)(5)

Our team is on a call with FDA now. I will share the messaging shortly.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>

Sent: Wednesday, May 26, 2021 2:26 PM

To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: RE: HAN

Sherri, Thanks so much, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 2:09 PM

To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: Re: HAN

Hi Dr. Levine,

The initial draft is with Rochelle now, flagging that you'd like to review as well.

Abbigail will work with the CDC STLT task force to set up a SHO call before it goes out to share the embargoed update with them via telephone.

Thank you,
Sherri

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 1:52 PM
To: Berger, Sherri (CDC/OCOO/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: HAN

Sherri, Good afternoon. I would also very much appreciate the opportunity to see the HAN before it is final.

As you noted, it would be great if we could give a heads-up to the group that Dr. Choucair speaks to on Tuesdays which includes ASTHO before it goes live.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 10:26 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Schuchat, Anne MD (CDC/OD)

<acs1@cdc.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Sams, Ian (HHS/ASPA <Ian.Sams@hhs.gov>

Subject: HAN Update

Importance: High

Hi all –

Abigail is tracking this, including rollout plans – as of 1AM, it is not ready to go today. I am letting her know Dawn and Sarah need an early heads up and to see the language beforehand.

Also, per chat, the SHOs requested a heads up (even if it is an hour before).

Thank you,
Sherri

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

From: Boateng, Sarah (HHS/OASH)
Sent: Tue, 25 May 2021 13:31:02 +0000
To: Levine, Rachel (HHS/OASH); Berger, Sherri (CDC/OCOO/OD)
Subject: FW: AAP News - Pediatricians should report cases of heart inflammation after COVID-19 vaccination
Attachments: AAP News - Pediatricians should report cases of heart inflammation after COVID-19 vaccination - 05_24_21.pdf

Hi Dr. Levine and Sherri

James flagged the attached. Sharing as FYI

Sarah

From: Baumberger, James (b)(6)
Sent: Tuesday, May 25, 2021 9:15 AM
To: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: AAP News - Pediatricians should report cases of heart inflammation after COVID-19 vaccination

Hi Sarah

I wanted you to see this AAP News article that was recently published and available to AAP members.

Best,
James

James Baumberger, MPP
Senior Director, Federal Advocacy
American Academy of Pediatrics
(b)(6)



Pediatricians should report cases of heart inflammation after COVID-19 vaccination

by Melissa Jenco, News Content Editor



Editor's note: For the latest news on COVID-19, visit <http://bit.ly/AAPNewsCOVID19>.

A small number of adolescents and young adults have experienced mild heart inflammation after receiving an mRNA COVID-19 vaccine, according to federal health officials. It is unclear whether the two are linked.

"We look forward to seeing more data about these cases so we can better understand if they are related to the vaccine or if they are coincidental," said Yvonne A. Maldonado, M.D., FAAP, chair of the AAP Committee on Infectious Diseases. "Meanwhile, it's important for pediatricians and other clinicians to report any health concerns that arise after vaccination to VAERS (the Vaccine Adverse Event Reporting System) so we can systematically track and analyze them, and determine if they signal a real concern."

The AAP continues to recommend that adolescents get vaccinated while health officials investigate cases of myocarditis, inflammation of the heart muscle.

More than 163 million people in the U.S. have received at least one dose of COVID-19 vaccine, including just over 4.5 million adolescents ages 12-17, CDC data show. There were "relatively few" cases of myocarditis after vaccination, according to a May 17 report from the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices COVID-19 Vaccine Safety Technical Work Group (VaST).

The report did not give a number but said the cases have been seen predominantly in adolescents and young adults and in more males than females. Cases are more common after the second dose of vaccine and typically occur within four days after vaccination. Most cases have been mild.

"Within CDC safety monitoring systems, rates of myocarditis reports in the window following COVID-19 vaccination have not differed from expected baseline rates," the report said. "However, VaST members felt that information about reports of myocarditis should be communicated to providers."



AAP News

The European Medicines Agency is looking into similar cases and said in a report earlier this month, "There is no indication at the moment that these cases are due to the vaccine."

Stuart Berger, M.D., FAAP, chair of the AAP Section on Cardiology and Cardiac Surgery Executive Committee, said in general, myocarditis is rare. Patients can be asymptomatic and often recover quickly. Most commonly, mild inflammation is related to a viral infection. This includes SARS-CoV-2 and the related multisystem inflammatory syndrome in children.

Symptoms that may prompt concern include chest pain, arrhythmias/palpitations and shortness of breath. Depending on severity, clinicians who believe a patient has myocarditis may order an EKG, echocardiogram, and testing for troponin levels, according to Dr. Berger. Treatment is supportive care for the symptoms.

"If you ever have a question, you ought to feel comfortable contacting your local pediatric cardiologist," said Dr. Berger, medical director of Lurie Children's Hospital Heart Center. "We certainly see it (myocarditis) more often than pediatricians. ... In the context of anything else, viral infections like COVID or the vaccine, we can be helpful in giving you advice also."

Children and adolescents experiencing myocarditis from any cause should talk to a pediatric cardiologist before returning to full participation in athletic activities. For cases occurring after vaccination, VaST also recommends clinicians consult with an infectious disease specialist and rheumatologist.

Health officials are closely monitoring safety systems as they investigate myocarditis cases after vaccination. Clinicians should report these cases to VAERS at <http://vaers.hhs.gov>.

Resources

- [CDC guidance on administering the Pfizer-BioNTech COVID-19 vaccine](#)
- [CDC COVID vaccination toolkit for pediatricians](#)
- [AAP guidance on providing COVID-19 vaccines to adolescents](#)
- [Information for parents from HealthyChildren.org on preparing children and adolescents for COVID-19 vaccination](#)
- [Video instructions on reporting to VAERS](#)

From: Brown, Tiffany J. (CDC/OCOO/OSSAM/OD)
Sent: Tue, 25 May 2021 21:36:57 +0000
To: Caudwell, Kerry M. (CDC/OD/OCS); Berger, Sherri (CDC/OCOO/OD)
Cc: CDC Reports (CDC)
Subject: RE: FOR REVIEW: CDC Cabinet Secretary Weekly Report for May 25 - updated template
Attachments: CDC Cabinet Secretary Weekly Report for May 25 2021 v2^tb.docx

Hi,

Please see my comments in the attached.

Flag item: (b)(5)

(b)(5) Additionally, we should be prepared to respond to questions from Clare and/or others.

Thank you,
Tiffany

From: Caudwell, Kerry M. (CDC/OD/OCS) <cli9@cdc.gov>
Sent: Tuesday, May 25, 2021 4:50 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Brown, Tiffany J. (CDC/OCOO/OSSAM/OD) <iji3@cdc.gov>
Cc: CDC Reports (CDC) <cdcreports@cdc.gov>
Subject: FOR REVIEW: CDC Cabinet Secretary Weekly Report for May 25 - updated template
Importance: High

Hi Sherri and Tiffany:

Action Needed: Attached, for your review, is CDC's input for the Cabinet Secretary Weekly Report that is due to HHS COB today.

The attachment reflects the template updates that were received from HHS last night (see email below and attachment). Revisions included:

(b)(5)

(b)(5)

Please let me know if you have any questions or comments.

Thanks,
Kerry

From: Briskin, Perrie (HHS/OS) <Perrie.Briskin@hhs.gov>

Sent: Monday, May 24, 2021 5:38:29 PM

To: Cochran, Norris (HHS/ASFR) <norris.cochran@hhs.gov>; Chang, Jooyeun (ACF) <Jooyeun.Chang@acf.hhs.gov>; Barkoff, Alison (ACL) <Alison.Barkoff@acl.hhs.gov>; Meyers, David (AHRQ/IOD) Deputy Director <David.Meyers@ahrq.hhs.gov>; Richter, Elizabeth (CMS/CM) <elizabeth.richter@cms.hhs.gov>; Espinosa, Diana (HRSA) <DEspinosa@hrsa.gov>; Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Coderre, Tom (SAMHSA/OPPI) <Tom.Coderre@samhsa.hhs.gov>; Seshasai, Karuna (HHS/IOS) <Karuna.Seshasai@hhs.gov>; Sullivan, Rose (HHS/ASL) <Rose.Sullivan@hhs.gov>; Bratcher-Bowman, Nikki (OS/ASPR/IO) <nikki.bratcherbowman@hhs.gov>; Lovenheim, Sarah (HHS/ASPA) <Sarah.Lovenheim@hhs.gov>; Frohboese, Robinsue (HHS/OCR) <Robinsue.Frohboese@HHS.GOV>; Barry, Daniel J (HHS/OGC) <daniel.barry@hhs.gov>; Grimm, Christi A (OIG/IO) <Christi.Grimm@oig.hhs.gov>; Figueroa, Marvin (HHS/IEA) <Marvin.Figueroa@hhs.gov>; Pace, Loyce (HHS/OS/OGA) <Loyce.Pace@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Woodcock, Janet (FDA/CDER) <Janet.Woodcock@fda.hhs.gov>; Fowler, Elizabeth A. (IHS/OKC/AO) <Elizabeth.Fowler@ihs.gov>; Haffajee, Rebecca (HHS/ASPE) <Rebecca.Haffajee@hhs.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Campbell, Cheryl (OS/ASA) <Cheryl.Campbell@hhs.gov>; Briskin, Perrie (HHS/OS) <Perrie.Briskin@hhs.gov>

Cc: Handerhan, Larry (ACF) <Larry.Handerhan@acf.hhs.gov>; Wright, Natasha (ACF) <Natasha.Wright@acf.hhs.gov>; Klocinski, Jennifer (ACL) <Jennifer.Klocinski@acl.hhs.gov>; Nicholls, Richard (ACL) <Richard.Nicholls@acl.hhs.gov>; Perry, Wendy (AHRQ/OD) <Wendy.Perry@ahrq.hhs.gov>; Bellios, Toulia (CMS/OSPR) <Toulia.Bellios@cms.hhs.gov>; Wu, Jeff (CMS/CCIIO) <Jeff.Wu@cms.hhs.gov>; Martino, Maria (CMS/OL) <Maria.Martino@cms.hhs.gov>; Goodman, Michelle (HRSA) <MGoodman@hrsa.gov>; Grossman, Jordan (HRSA) <JGrossman@hrsa.gov>; Patel, Nisha (HRSA) <NPatel@hrsa.gov>; Heppner, Eliza (HRSA) <ehheppner@hrsa.gov>; ESHHSReportsTeam@nih.gov <ESHHSReportsTeam@nih.gov>; Tabak, Lawrence (NIH/OD) [E] <Lawrence.Tabak@nih.gov>; Allen-Gifford, Patrice (NIH/OD) [E] <patrice.allen-gifford@nih.gov>; Gallardo, Daniel (SAMHSA/OAS) <Daniel.Gallardo@samhsa.hhs.gov>; Chessen, Sonia (SAMHSA/OAS) <Sonia.Chessen@samhsa.hhs.gov>; Gallardo, Daniel (SAMHSA/OAS) <Daniel.Gallardo@samhsa.hhs.gov>; Robinson, Wilma (HHS/IOS) <Wilma.Robinson@hhs.gov>; Tatem, Anne (HHS/OS/ASL) <Anne.Tatem@hhs.gov>; Espinosa, Kimberly (HHS/ASL) <Kimberly.Espinosa@hhs.gov>; Hild, Jeff (HHS/ASL) <Jeff.Hild@hhs.gov>; Perry, Ijeoma (OS/ASPR/EMMO) <Ijeoma.Perry@hhs.gov>; Wulff, Kacey (OS/ASPR/IO) <Kacey.Wulff@hhs.gov>; Alvarez, Kathryn (OS/IOS) <Kathryn.Alvarez@hhs.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Lynk, Beth (HHS/ASPA) <Florence.Lynk@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Peck, Joshua (HHS/ASPA) <Joshua.Peck@hhs.gov>; Weber, Mark (HHS/ASPA) <Mark.Weber@hhs.gov>; Henderson, Harold (HHS/OCR) <Harold.Henderson@hhs.gov>; Durso, Laura (HHS/OCR) <Laura.Durso@hhs.gov>; Akpa, Stephanie (HHS/OCR)

<Stephanie.Akpa@hhs.gov>; Tobias, Constance (HHS/DAB) <Constance.Tobias@hhs.gov>; Scott, Katherine (OS/DAB) <Katherine.Scott@hhs.gov>; Howard, Lemuel (OS/DAB) <Lemuel.Howard@hhs.gov>; Montgomery, Meredith (HHS/DAB) <Meredith.Montgomery@hhs.gov>; Barclay, Lisa (HHS/OGC) <Lisa.Barclay@hhs.gov>; Rodriguez, Paul (HHS/OGC) <PaulR.Rodriguez@hhs.gov>; McGarey, Barbara (HHS/OGC) <Barbara.McGarey@hhs.gov>; Keveney, Sean (HHS/OGC) <Sean.Keveney@hhs.gov>; Allen, McArthur (HHS/OMHA) <Mcarthur.Allen@hhs.gov>; Shelton, Carrie A (HHS/OS/OMHA) <Carrie.Shelton@HHS.GOV>; McGuinness, Laura (OS/OMHA) <Laura.McGuinness@hhs.gov>; Tripathi, Micky (OS/ONC) <Micky.Tripathi@hhs.gov>; Swain, Matthew (OS/ONC) <Matthew.Swain@hhs.gov>; Kost, Michelle (OS/ONC) <Michelle.Kost@hhs.gov>; Stevens, Lee (OS/IEA) <Lee.Stevens@hhs.gov>; Mciff, Colin (HHS/OS/OGA) <Colin.Mciff@hhs.gov>; Psaki, Stephanie (HHS/OS/OGA) <Stephanie.Psaki@hhs.gov>; Schaeffer, Alison (HHS/OS/OGA) <Alison.Schaeffer@hhs.gov>; LaHood, Natalie (OS/OGA) <Natalie.Lahood@hhs.gov>; Tcholakian, Karoun (HHS/OS/OGA) <Karoun.Tcholakian@hhs.gov>; Caudwell, Kerry M. (CDC/OD/OCS) <cli9@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Brown, Tiffany J. (CDC/OCOO/OSSAM/OD) <ijj3@cdc.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Tobias, Lindsay (FDA/OC) <Lindsay.Tobias@fda.hhs.gov>; Church, Ann M. (IHS/HQ) <Ann.Church@ihs.gov>; Carr, Elizabeth (IHS/HQ) <Elizabeth.Carr@ihs.gov>; Kim, Shalley (OS/ASA) <Shalley.Kim@hhs.gov>; Duncan, Blair (OS/ASA) <Blair.Duncan@hhs.gov>; Swenson-O'Brien, Alicia (OS/ASPE) <Alicia.Swenson-O'Brien@hhs.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Handley, Elisabeth (OS/OASH/ORI) <Elisabeth.Handley@hhs.gov>; Oh, Kathy J. (CMS/OHC) <Kathy.Oh@cms.hhs.gov>; Fisher, Megan (HHS/OASH) <Megan.Fisher@hhs.gov>; Pryor, Rachel (HHS/OS/IOS) <Rachel.Pryor@hhs.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Villanueva, Josie (OS/IOS) <Josie.Villanueva@hhs.gov>; Rainer, Melanie Fontes (OS/IOS) <Melanie.Rainer@hhs.gov>; Cha, Stephen (HHS/IOS) <Stephen.Cha@hhs.gov>; Lopez, Steven (HHS/OS/IOS) <Steven.Lopez@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>; Reid, Anne (OS/IOS) <Anne.Reid@hhs.gov>; Mccluskie, Sean (HHS/IOS) <Sean.Mccluskie@hhs.gov>; Harris, James (HHS/Partnership Center) <James.Harris3@hhs.gov>; Orozco, Esmeralda (HHS/IOS) <Esmeralda.Orozco@hhs.gov>; Palafox, Cynthia (HHS/IOS) <Cynthia.Palafox@hhs.gov>

Subject: Weekly Cabinet Affairs Report - New Template and Guidance

Hello,

We have received the below guidance and update template attached from Cabinet Affairs. The most significant updates are to additional sections in the Appendix.

As always, please submit your division's reports to me and Clare by COB tomorrow, Tuesday.

Also, as an FYI, the counselors are now doing a closer review of divisions' weekly reports before the final report goes to Cabinet Affairs.

Thank you. Please let me and Clare know if you have any questions.

Best,
Perrie

5/24 Weekly Cabinet Affairs Report Guidance

Main report sections:

- **Audience reminder:** Please remember that you are writing for an audience that is not steeped in the policy expertise or acronyms of your agency. As such, when you include an item please make sure your description is succinct, includes enough context to be understood by a layperson, and answers the inherent question of why this item is important.
- **Setbacks/Obstacles:** The accomplishments are important, and it's also important for White House offices to be aware of setbacks and obstacles. Please include these, and where something is more sensitive you're welcome to call or email our team to discuss instead.

Appendix section:

- **4-week look-ahead:** In the Appendix, please list items covering the previous week and the look ahead for 4 weeks out.
- If something is tentative or the date is TBD, please include and note accordingly.
- If something was scheduled and changes or gets cancelled, please let us know directly or include that update in the next week's report.
- **Travel template for Cabinet members:** For Cabinet Member travel going forward, please provide the details for each expected trip at least 4 weeks out in the following format:
- **Date – Location(s):** Topline event description, including type of event (roundtable, tour, etc.), participants, and topic (ARP, AJP, AFP, etc.)
- **Example: May 31st – Ford Plant in Dearborn, Michigan:** Secretary Granholm will participate in a roundtable with Ford executives and United Auto Workers (UAW) members to discuss electric vehicles and how both AJP and AFP will support U.S. competitiveness, create good-paying jobs and help us reach climate goals. Senators Gary Peters (D-MI) and Debbie Stabenow (D-MI) and Governor Gretchen Whitmer (D-MI) have been invited. We expect to notice this event on May 28th.
- **New sections for funding and grant announcements:** At the request of the Domestic Policy Council, we have added new separate sections for you to list grant notices (NOFA/NOFOs) and funding announcements.
- For all Appendix items, please indicate where an engagement is specific to ARP, AJP, AFP, or other priorities.

Date Formatting: Please include ordinal indicators (rd/th/nd/st) after numbers (no superscript), and do not include year unless referring to an earlier/future year that requires clarification.

Perrie Briskin
 Senior Advisor to the Chief of Staff
 U.S. Department of Health and Human Services
 Cell: (b)(6)
Perrie.Briskin@hhs.gov

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

From: Caudwell, Kerry M. (CDC/OD/OCS)
Sent: Tue, 25 May 2021 22:34:40 +0000
To: Pierce-Wrobel, Clare (HHS/OS; Briskin, Perrie (HHS/OS
Cc: Berger, Sherri (CDC/OCOO/OD); Brown, Tiffany J. (CDC/OCOO/OSSAM/OD);
Despres, Sarah (HHS/IOS; CDC Reports (CDC)
Subject: CDC Cabinet Secretary Weekly Report for May 25
Attachments: CDC Cabinet Secretary Weekly Report for May 25, 2021.docx
Importance: High

Hi there Clare and Perrie:

Please find attached CDC's submission for the Cabinet Secretary Weekly Report, using the updated template we received yesterday.

Should you have any questions regarding the report, feel free to reach out to Sherri Berger at 404-639-7846.

Take care,

Kerry

Kerry Caudwell, MPA
Office of the Chief of Staff
Centers for Disease Control and Prevention
Cell: 404 200 5190 Office: 404 639 0390

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

From: Levine, Rachel (HHS/OASH)
Sent: Sat, 29 May 2021 16:57:40 +0000
To: Walensky, Rochelle (CDC/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: Re: AAP
Attachments: image004.jpg, image005.jpg

Rochelle, good afternoon. Thanks so much. Take care, Rachel

Sent from my iPhone

On May 29, 2021, at 9:37 AM, Walensky, Rochelle (CDC/OD) <aux7@cdc.gov> wrote:

Hi Rachel,

Good morning. Thank you so much for engaging in this call and for this information. I was thinking that

(b)(5)

Many thanks,
Rochelle

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Saturday, May 29, 2021 9:24 AM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP
Importance: High

Rochelle, Good morning. I hope that you are well.

We just got off of the phone with the AAP and the Section on Pediatric Cardiology and reviewed these questions.

They confirmed the validity and importance of the guidelines.

Certainly myocarditis with Covid 19 is uncommon and even more uncommon with the vaccines- if it is associated at all with the vaccines.

However, if myocarditis is diagnosed, with corroborating labs, EKG, echo etc., then they would follow the AHA class 1 guidelines as you noted below.

They would recommend 3-6 months of limitations on sports as outlined depending on the severity of the case.

They highlighted the significant risks that can be associated with adolescent myocarditis and the collaboration of primary care and the pediatric cardiology in working with the young person and the families.

In summary, they all felt that the treatment had to be consistent with the recommendations as noted below no matter the precipitating cause.

Please let me know your thoughts.

We are pleased to jump on a call anytime.
Take care, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

<image003.png>

Email: rachel.levine@hhs.gov
hhs.gov/ash

<image004.jpg>

From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Friday, May 28, 2021 12:51 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP

Hi Rachel,
I'm so grateful for your help here.
So, I'm deep in the weeds (and perhaps too much so) but I'd like to understand how they are thinking about this.

(b)(5)

Recommendations

(b)(5)

(b)(5)

Thank you!

R

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Friday, May 28, 2021 12:11 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: AAP

Rochelle, Thank you for your call. I checked and the AAP did come out with guidance referencing the CDC recommendations and did emphasize continued vaccinations.

<https://www.aappublications.org/news/2021/05/27/covid-vaccine-myocarditis-guidance-052721>

I can still check with them about the exercise recommendations for adolescents with mild myocarditis. Please give me your thoughts.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

<image005.jpg>

Email: rachel.levine@hhs.gov
hhs.gov/ash

✘

QASR

قصر
الاسكندرية
المتحف
الاسكندرية

From: Berger, Sherri (CDC/OCOO/OD)
Sent: Sat, 29 May 2021 15:20:40 +0000
To: Boateng, Sarah (HHS/OASH)
Subject: Re: AAP

Thanks for sharing!

From: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Sent: Saturday, May 29, 2021 9:31:38 AM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Subject: Fwd: AAP

FYI

Sent from my iPhone

Begin forwarded message:

From: "Levine, Rachel (HHS/OASH)" <Rachel.Levine@hhs.gov>
Date: May 29, 2021 at 9:23:43 AM EDT
To: "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>
Cc: "Boateng, Sarah (HHS/OASH)" <Sarah.Boateng@hhs.gov>
Subject: RE: AAP

Rochelle, Good morning. I hope that you are well.

We just got off of the phone with the AAP and the Section on Pediatric Cardiology and reviewed these questions.

They confirmed the validity and importance of the guidelines.

Certainly myocarditis with Covid 19 is uncommon and even more uncommon with the vaccines- if it is associated at all with the vaccines.

However, if myocarditis is diagnosed, with corroborating labs, EKG, echo etc., then they would follow the AHA class 1 guidelines as you noted below.

They would recommend 3-6 months of limitations on sports as outlined depending on the severity of the case.

They highlighted the significant risks that can be associated with adolescent myocarditis and the collaboration of primary care and the pediatric cardiology in working with the young person and the families.

In summary, they all felt that the treatment had to be consistent with the recommendations as noted below no matter the precipitating cause.

Please let me know your thoughts.

We are pleased to jump on a call anytime.

Take care, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Friday, May 28, 2021 12:51 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP

Hi Rachel,
I'm so grateful for your help here.
So, I'm deep in the weeds (and perhaps too much so) but I'd like to understand how they are thinking about this.

(b)(5)

Recommendations

(b)(5)

(b)(5)

Thank you!

R

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>

Sent: Friday, May 28, 2021 12:11 PM

To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>

Subject: AAP

Rochelle, Thank you for your call. I checked and the AAP did come out with guidance referencing the CDC recommendations and did emphasize continued vaccinations.

<https://www.aappublications.org/news/2021/05/27/covid-vaccine-myocarditis-guidance-052721>

I can still check with them about the exercise recommendations for adolescents with mild myocarditis.

Please give me your thoughts.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

—

Email: rachel.levine@hhs.gov
hhs.gov/ash

✕

From: Weakland, Aliko P. (CDC/DDID/NCEZID/DPEI)
Sent: Thu, 27 May 2021 16:20:15 +0000
To: Boateng, Sarah (HHS/OASH); Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)
Cc: Berger, Sherri (CDC/OCOO/OD); Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP)
Subject: RE: Myocarditis Materials

Got it – will amend Run of Show and send in a moment

Aliko Pappas Weakland, MPH MSW (she/her/hers)

Lead, Policy & Public Health Partnerships
State, Tribal, Local and Territorial Support Task Force
Coronavirus Disease-2019 (COVID-19) Response
Centers for Disease Control and Prevention (CDC)
e: app4@cdc.gov
o: 404.498.0234
m: 678.488.7327

Policy inquiries: eocevent382@cdc.gov
Partnership inquiries: eocevent424@cdc.gov

[Coronavirus Disease 2019 \(COVID-19\) | CDC](#)

From: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Sent: Thursday, May 27, 2021 10:18 AM
To: Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>
Subject: Re: Myocarditis Materials

Sure. Yes. She can say a very brief welcome


Sent from my iPhone

On May 27, 2021, at 11:41 AM, Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov> wrote:

Will have the invite forwarded for to you Dr. Levine to join as a panelist. Does she want to share any remarks during the call as part of the opening?

Margaret (Peggy) Honein, PhD, MPH
COVID-19 Emergency Response
U.S. Centers for Disease Control and Prevention

mrh7@cdc.gov



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 11:39 AM
To: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>
Subject: Re: Myocarditis Materials

Hi Sarah! The time is moving — happy to have her join. Others here will coordinate with you directly.
Thanks

From: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Sent: Thursday, May 27, 2021 11:31 AM
To: Berger, Sherri (CDC/OCOO/OD)
Subject: RE: Myocarditis Materials

Sherri

Would you like Dr. Levine on the 12:30pm?

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 11:07 AM
To: Tumpey, Abigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/OC) <Julia.Tierney@fda.hhs.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: Myocarditis Materials

FYI – there is a 1230PM call with STLT and core PH partners and we were planning to give an EMBARGOED heads up. Thanks

From: Tumpey, Abigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Thursday, May 27, 2021 10:19 AM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER)

<Julia.Tierney@fda.hhs.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

Subject: Myocarditis Materials

Dr. Levine, Dawn,

Attached are the pieces of the myocarditis content that are still in final review at CDC.

They include:

(b)(5)

Please let us know if you have additional questions or concerns.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Sent: Thursday, May 27, 2021 9:27 AM

To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>

Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>

Subject: RE: HAN

Good morning –

I believe the email below is still the current plan. As a reminder, both the ASH and Dawn would like to see the draft messages before we finalize/distribute. And, we should do the SHO outreach right beforehand.

Thanks,
Sherri

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Wednesday, May 26, 2021 6:08 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>
Subject: RE: HAN

Dr. Levine,

We are still discussing the strategy on this topic. However, after discussions internally and with FDA, we

(b)(5)

Our team is on a call with FDA now. I will share the messaging shortly.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 2:26 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: RE: HAN


Sherri, Thanks so much, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

—
Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 2:09 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: Re: HAN

Hi Dr. Levine,

The initial draft is with Rochelle now, flagging that you'd like to review as well.

Abigail will work with the CDC STLT task force to set up a SHO call before it goes out to share the embargoed update with them via telephone.

Thank you,
Sherri

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 1:52 PM
To: Berger, Sherri (CDC/OCOO/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: HAN

Sherri, Good afternoon. I would also very much appreciate the opportunity to see the HAN before it is final.
As you noted, it would be great if we could give a heads-up to the group that Dr. Choucair speaks to on Tuesdays which includes ASTHO before it goes live.
Thanks, Rachel

Rachel L. Levine, M.D.
Assistant Secretary for Health
Office of the Assistant Secretary for Health

—

Email: rachel.levine@hhs.gov
hhs.gov/ash

x] x]

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 10:26 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Subject: HAN Update
Importance: High

Hi all –

Abbigail is tracking this, including rollout plans – as of 1AM, it is not ready to go today. I am letting her know Dawn and Sarah need an early heads up and to see the language beforehand.

Also, per chat, the SHOs requested a heads up (even if it is an hour before).

Thank you,
Sherri

From: Walensky, Rochelle (CDC/OD)
Sent: Sat, 29 May 2021 13:36:14 +0000
To: Levine, Rachel (HHS/OASH)
Cc: Boateng, Sarah (HHS/OASH)
Subject: RE: AAP

Voila...

(b)(5)

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Saturday, May 29, 2021 9:24 AM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP
Importance: High

Rochelle, Good morning. I hope that you are well.

We just got off of the phone with the AAP and the Section on Pediatric Cardiology and reviewed these questions.

They confirmed the validity and importance of the guidelines.

Certainly myocarditis with Covid 19 is uncommon and even more uncommon with the vaccines- if it is associated at all with the vaccines.

However, if myocarditis is diagnosed, with corroborating labs, EKG, echo etc., then they would follow the AHA class 1 guidelines as you noted below.

They would recommend 3-6 months of limitations on sports as outlined depending on the severity of the case.

They highlighted the significant risks that can be associated with adolescent myocarditis and the collaboration of primary care and the pediatric cardiology in working with the young person and the families.

In summary, they all felt that the treatment had to be consistent with the recommendations as noted below no matter the precipitating cause.

Please let me know your thoughts.

We are pleased to jump on a call anytime.

Take care, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
[hhs.gov/ash](https://www.hhs.gov/ash)



From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Friday, May 28, 2021 12:51 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP

Hi Rachel,
I'm so grateful for your help here.
So, I'm deep in the weeds (and perhaps too much so) but I'd like to understand how they are thinking about this.

(b)(5)

Recommendations

(b)(5)

So my general question (sorry so long) is:

(b)(5)

Thank you!

R

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>

Sent: Friday, May 28, 2021 12:11 PM

To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>

Subject: AAP

Rochelle, Thank you for your call. I checked and the AAP did come out with guidance referencing the CDC recommendations and did emphasize continued vaccinations.

<https://www.aappublications.org/news/2021/05/27/covid-vaccine-myocarditis-guidance-052721>

I can still check with them about the exercise recommendations for adolescents with mild myocarditis. Please give me your thoughts.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov

hhs.gov/ash

✕

From: Walensky, Rochelle (CDC/OD)
Sent: Sat, 29 May 2021 13:34:48 +0000
To: Levine, Rachel (HHS/OASH)
Cc: Boateng, Sarah (HHS/OASH)
Subject: RE: AAP

Hi Rachel,

Good morning. Thank you so much for engaging in this call and for this information. I was thinking that

(b)(5)

Many thanks,
Rochelle

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Saturday, May 29, 2021 9:24 AM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP
Importance: High

Rochelle, Good morning. I hope that you are well.

We just got off of the phone with the AAP and the Section on Pediatric Cardiology and reviewed these questions.

They confirmed the validity and importance of the guidelines.

Certainly myocarditis with Covid 19 is uncommon and even more uncommon with the vaccines- if it is associated at all with the vaccines.

However, if myocarditis is diagnosed, with corroborating labs, EKG, echo etc., then they would follow the AHA class 1 guidelines as you noted below.

They would recommend 3-6 months of limitations on sports as outlined depending on the severity of the case.

They highlighted the significant risks that can be associated with adolescent myocarditis and the collaboration of primary care and the pediatric cardiology in working with the young person and the families.

In summary, they all felt that the treatment had to be consistent with the recommendations as noted below no matter the precipitating cause.

Please let me know your thoughts.

We are pleased to jump on a call anytime.

Take care, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Friday, May 28, 2021 12:51 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP

Hi Rachel,
I'm so grateful for your help here.
So, I'm deep in the weeds (and perhaps too much so) but I'd like to understand how they are thinking about this.

(b)(5)

Recommendations

(b)(5)

(b)(5)

Thank you!

R

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Friday, May 28, 2021 12:11 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: AAP

Rochelle, Thank you for your call. I checked and the AAP did come out with guidance referencing the CDC recommendations and did emphasize continued vaccinations.

<https://www.aappublications.org/news/2021/05/27/covid-vaccine-myocarditis-guidance-052721>

I can still check with them about the exercise recommendations for adolescents with mild myocarditis. Please give me your thoughts.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov

hhs.gov/ash

✕

From: Levine, Rachel (HHS/OASH)
Sent: Fri, 28 May 2021 16:56:42 +0000
To: Walensky, Rochelle (CDC/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: RE: AAP

Rochelle, Thanks for your email and the information. We are checking with the AAP and the Pediatric Cardiologists and will keep you up to date. Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health


Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Friday, May 28, 2021 12:51 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP

Hi Rachel,
I'm so grateful for your help here.
So, I'm deep in the weeds (and perhaps too much so) but I'd like to understand how they are thinking about this.

(b)(5)



Recommendations

(b)(5)

Thank you!

R

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Friday, May 28, 2021 12:11 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: AAP

Rochelle, Thank you for your call. I checked and the AAP did come out with guidance referencing the CDC recommendations and did emphasize continued vacciantions.

<https://www.aappublications.org/news/2021/05/27/covid-vaccine-myocarditis-guidance-052721>

I can still check with them about the exercise recommendations for adolescents with mild myocarditis. Please give me your thoughts.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

.....

Email: rachel.levine@hhs.gov
hhs.gov/ash

✕

From: Levine, Rachel (HHS/OASH)
Sent: Fri, 28 May 2021 20:55:43 +0000
To: Walensky, Rochelle (CDC/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: RE: AAP

Rochelle, I am speaking with the AAP and the Pediatric Cardiologists about these issues tomorrow at 9 am. I will keep you up to date. Take care, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Friday, May 28, 2021 12:51 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: RE: AAP

Hi Rachel,
I'm so grateful for your help here.
So, I'm deep in the weeds (and perhaps too much so) but I'd like to understand how they are thinking about this.

(b)(5)



Recommendations

(b)(5)

Thank you!

R

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Friday, May 28, 2021 12:11 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: AAP

Rochelle, Thank you for your call. I checked and the AAP did come out with guidance referencing the CDC recommendations and did emphasize continued vacciantions.

<https://www.aappublications.org/news/2021/05/27/covid-vaccine-myocarditis-guidance-052721>

I can still check with them about the exercise recommendations for adolescents with mild myocarditis. Please give me your thoughts.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

.....

Email: rachel.levine@hhs.gov
hhs.gov/ash

✕

From: Walensky, Rochelle (CDC/OD)
Sent: Fri, 28 May 2021 16:51:15 +0000
To: Levine, Rachel (HHS/OASH)
Cc: Boateng, Sarah (HHS/OASH)
Subject: RE: AAP

Hi Rachel,
I'm so grateful for your help here.
So, I'm deep in the weeds (and perhaps too much so) but I'd like to understand how they are thinking about this.

(b)(5)

Recommendations

(b)(5)

So my general question (sorry so long) is:

(b)(5)

Thank you!

R

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>

Sent: Friday, May 28, 2021 12:11 PM

To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>

Subject: AAP

Rochelle, Thank you for your call. I checked and the AAP did come out with guidance referencing the CDC recommendations and did emphasize continued vaccinations.

<https://www.aappublications.org/news/2021/05/27/covid-vaccine-myocarditis-guidance-052721>

I can still check with them about the exercise recommendations for adolescents with mild myocarditis.

Please give me your thoughts.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health

Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov

hhs.gov/ash

✕

From: O'Connell, Dawn (HHS/IOS)
Sent: Thu, 27 May 2021 15:40:54 +0000
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD); Berger, Sherri (CDC/OCOO/OD); Levine, Rachel (HHS/OASH)
Cc: Boateng, Sarah (HHS/OASH); Sams, Ian (HHS/ASPA); Broido, Tara (HHS/OASH); Tierney, Julia (FDA/CBER); Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP); Beckman, Adam (HHS/OASH); Phillips, Alexandria (HHS/OASH); Caccomo, Stephanie (FDA/OC); Walensky, Rochelle (CDC/OD)
Subject: RE: Myocarditis Materials

Thanks. Good here.

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Thursday, May 27, 2021 11:35 AM
To: O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/OC) <Julia.Tierney@fda.hhs.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: Myocarditis Materials

Dawn,

We were planning to post this between 2-3pm.

Received some additional comments/questions from Courtney Rowe that I am addressing.

Any additional concerns?

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Sent: Thursday, May 27, 2021 11:25 AM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: Myocarditis Materials

So you all will go at 1?

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 11:07 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/OC) <Julia.Tierney@fda.hhs.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: Myocarditis Materials

FYI – there is a 1230PM call with STLT and core PH partners and we were planning to give an EMBARGOED heads up. Thanks

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Thursday, May 27, 2021 10:19 AM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: Myocarditis Materials

Dr. Levine, Dawn,

Attached are the pieces of the myocarditis content that are still in final review at CDC.

They include:

(b)(5)

Please let us know if you have additional questions or concerns.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 9:27 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>
Subject: RE: HAN

Good morning –

I believe the email below is still the current plan. As a reminder, both the ASH and Dawn would like to see the draft messages before we finalize/distribute. And, we should do the SHO outreach right beforehand.

Thanks,
Sherri

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Wednesday, May 26, 2021 6:08 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Berger, Sherri (CDC/OCOO/OD)

<sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>
Subject: RE: HAN

Dr. Levine,

We are still discussing the strategy on this topic. However, after discussions internally and with FDA, we

(b)(5)

Our team is on a call with FDA now. I will share the messaging shortly.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 2:26 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: RE: HAN

Sherri, Thanks so much, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 2:09 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: Re: HAN

Hi Dr. Levine,

The initial draft is with Rochelle now, flagging that you'd like to review as well.

Abbigail will work with the CDC STLT task force to set up a SHO call before it goes out to share the embargoed update with them via telephone.

Thank you,
Sherri

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 1:52 PM
To: Berger, Sherri (CDC/OCOO/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: HAN

Sherri, Good afternoon. I would also very much appreciate the opportunity to see the HAN before it is final.

As you noted, it would be great if we could give a heads-up to the group that Dr. Choucair speaks to on Tuesdays which includes ASTHO before it goes live.

Thanks, Rachel

Rachel L. Levine, M.D.
Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash

x] x]

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 10:26 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>
Subject: HAN Update
Importance: High

Hi all –

Abbigail is tracking this, including rollout plans – as of 1AM, it is not ready to go today. I am letting her know Dawn and Sarah need an early heads up and to see the language beforehand.

Also, per chat, the SHOs requested a heads up (even if it is an hour before).

Thank you,
Sherri

From: Levine, Rachel (HHS/OASH)
Sent: Fri, 28 May 2021 00:16:38 +0000
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)
Cc: O'Connell, Dawn (HHS/IOS); Boateng, Sarah (HHS/OASH); Sams, Ian (HHS/ASPA); Broido, Tara (HHS/OASH); Tierney, Julia (FDA/CBER); Beckman, Adam (HHS/OASH); Phillips, Alexandria (HHS/OASH); Berger, Sherri (CDC/OCOO/OD); Caccomo, Stephanie (FDA/OC); Walensky, Rochelle (CDC/OD)
Subject: Re: Myocarditis Materials

Good evening
Thank you very much
Rachel

Sent from my iPhone

On May 27, 2021, at 7:49 PM, Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov> wrote:

Dr. Levine,
This is content posted.
Public content: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html>

Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html>

Regards,
Abbigail


From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Thursday, May 27, 2021 10:35 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD); O'Connell, Dawn (HHS/IOS)
Cc: Boateng, Sarah (HHS/OASH); Sams, Ian (HHS/ASPA); Broido, Tara (HHS/OASH); Tierney, Julia (FDA/CBER); Beckman, Adam (HHS/OASH); Phillips, Alexandria (HHS/OASH); Berger, Sherri (CDC/OCOO/OD); Caccomo, Stephanie (FDA/OC); Walensky, Rochelle (CDC/OD)
Subject: RE: Myocarditis Materials

Abbigail, Good morning. Thank you so much. Looks great. Please keep me up to date, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Thursday, May 27, 2021 10:19 AM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/OC) <Julia.Tierney@fda.hhs.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: Myocarditis Materials

Dr. Levine, Dawn,

Attached are the pieces of the myocarditis content that are still in final review at CDC.

They include:



Please let us know if you have additional questions or concerns.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 9:27 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>
Subject: RE: HAN

Good morning –

I believe the email below is still the current plan. As a reminder, both the ASH and Dawn would like to see the draft messages before we finalize/distribute. And, we should do the SHO outreach right beforehand.

Thanks,
Sherri

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Wednesday, May 26, 2021 6:08 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>
Subject: RE: HAN

Dr. Levine,

We are still discussing the strategy on this topic. However, after discussions internally and with FDA, we

(b)(5)

Our team is on a call with FDA now. I will share the messaging shortly.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention

1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov


From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 2:26 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: RE: HAN

Sherri, Thanks so much, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 2:09 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: Re: HAN

Hi Dr. Levine,

The initial draft is with Rochelle now, flagging that you'd like to review as well.

Abbigail will work with the CDC STLT task force to set up a SHO call before it goes out to share the embargoed update with them via telephone.

Thank you,
Sherri

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 1:52 PM
To: Berger, Sherri (CDC/OCOO/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: HAN

Sherri, Good afternoon. I would also very much appreciate the opportunity to see the HAN before it is final.

As you noted, it would be great if we could give a heads-up to the group that Dr. Choucair speaks to on Tuesdays which includes ASTHO before it goes live.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

—

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 10:26 AM
To: Tumpey, Abigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Subject: HAN Update
Importance: High

Hi all –

Abigail is tracking this, including rollout plans – as of 1AM, it is not ready to go today. I am letting her know Dawn and Sarah need an early heads up and to see the language beforehand.

Also, per chat, the SHOs requested a heads up (even if it is an hour before).

Thank you,
Sherri

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)
Sent: Thu, 27 May 2021 15:34:30 +0000
To: O'Connell, Dawn (HHS/IOS); Berger, Sherri (CDC/OCOO/OD); Levine, Rachel (HHS/OASH)
Cc: Boateng, Sarah (HHS/OASH); Sams, Ian (HHS/ASPA); Broido, Tara (HHS/OASH); Tierney, Julia (FDA/CBER); Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP); Beckman, Adam (HHS/OASH); Phillips, Alexandria (HHS/OASH); Caccomo, Stephanie (FDA/OC); Walensky, Rochelle (CDC/OD)
Subject: RE: Myocarditis Materials

Dawn,

We were planning to post this between 2-3pm.

Received some additional comments/questions from Courtney Rowe that I am addressing.

Any additional concerns?

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Sent: Thursday, May 27, 2021 11:25 AM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: Myocarditis Materials

So you all will go at 1?

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 11:07 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/OC) <Julia.Tierney@fda.hhs.gov>; Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: Myocarditis Materials

FYI – there is a 1230PM call with STLT and core PH partners and we were planning to give an EMBARGOED heads up. Thanks

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Thursday, May 27, 2021 10:19 AM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Beckman, Adam (HHS/OASH) <Adam.Beckman@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: Myocarditis Materials

Dr. Levine, Dawn,

Attached are the pieces of the myocarditis content that are still in final review at CDC.

They include:

(b)(5)

Please let us know if you have additional questions or concerns.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 9:27 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>
Subject: RE: HAN

Good morning –

I believe the email below is still the current plan. As a reminder, both the ASH and Dawn would like to see the draft messages before we finalize/distribute. And, we should do the SHO outreach right beforehand.

Thanks,
Sherri

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Sent: Wednesday, May 26, 2021 6:08 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>
Subject: RE: HAN

Dr. Levine,

We are still discussing the strategy on this topic. However, after discussions internally and with FDA, we

(b)(5)

Our team is on a call with FDA now. I will share the messaging shortly.

Regards,

Abbigail

Abbigail Tumpey, MPH CHES
Acting Associate Director for Communication
Centers for Disease Control and Prevention
1600 Clifton Rd. NE
Atlanta, GA
Phone: 404-639-1125
Cell: 404-259-7064
Email: atumpey@cdc.gov

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 2:26 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: RE: HAN

Sherri, Thanks so much, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 2:09 PM
To: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Subject: Re: HAN

Hi Dr. Levine,

The initial draft is with Rochelle now, flagging that you'd like to review as well.

Abbigail will work with the CDC STLT task force to set up a SHO call before it goes out to share the embargoed update with them via telephone.

Thank you,
Sherri

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Wednesday, May 26, 2021 1:52 PM
To: Berger, Sherri (CDC/OCOO/OD)
Cc: Boateng, Sarah (HHS/OASH)
Subject: HAN

Sherri, Good afternoon. I would also very much appreciate the opportunity to see the HAN before it is final.

As you noted, it would be great if we could give a heads-up to the group that Dr. Choucair speaks to on Tuesdays which includes ASTHO before it goes live.

Thanks, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash



From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, May 26, 2021 10:26 AM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP) <yzq5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Sams, Ian (HHS/ASPA) <lan.Sams@hhs.gov>
Subject: HAN Update
Importance: High

Hi all –

Abbigail is tracking this, including rollout plans – as of 1AM, it is not ready to go today. I am letting her know Dawn and Sarah need an early heads up and to see the language beforehand.

Also, per chat, the SHOs requested a heads up (even if it is an hour before).

Thank you,
Sherri

From: Walensky, Rochelle (CDC/OD)
Sent: Fri, 14 May 2021 22:49:45 +0000
To: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID)
Subject: FW: what do you think about this?
Attachments: Myocarditis_V4.docx

From: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Sent: Friday, May 14, 2021 6:47 PM
To: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: what do you think about this?

x]

--

Ian Sams
Deputy Assistant Secretary for Public Affairs (COVID Response)
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services
(202) 740-7169
ian.sams@hhs.gov

Myocarditis Email

Subject: For Awareness: ~~Investigating-Monitoring Reports of Myocarditis After Vaccination~~

Good afternoon,

~~In recent weeks, there have been reports CDC is aware of rare reports of myocarditis occurring after COVID-19 vaccination, including in Europe, where the EMA recently XXXXXX, and CDC is aware of these reports and continues to monitor available data investigating these reports.~~

Commented [SI(1)]: Need help on what the short, one-phrase description of this is

Myocarditis is the inflammation of the heart muscle and pericarditis is the inflammation of the lining outside the heart. In both cases, the body's immune system is causing inflammation in response to an infection or some other trigger. While myocarditis can be serious, it is frequently mild and self-limited.

As part of COVID-19 vaccine safety efforts, we have been closely monitoring myocarditis/pericarditis in multiple safety systems, including the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Data-link (VSD).

To date, there has not been a safety signal identified in either VAERS or VSD. CDC will continue to evaluate reports of myocarditis/pericarditis occurring after COVID-19 vaccination and will share more information as it becomes available. Healthcare providers should consider myocarditis in an evaluation of chest pain after vaccination and report all cases to VAERS.

CDC continues to recommend COVID-19 vaccination for people 12 years and older.

Thank you

From: Walensky, Rochelle (CDC/OD)
Sent: Tue, 25 May 2021 23:46:49 +0000
To: Levine, Rachel (HHS/OASH)
Cc: Boateng, Sarah (HHS/OASH)
Subject: Re: Meeting with Pediatric Cardiologists

Rachel,
Wow, thank you so much for this super helpful engagement. We don't yet have a ton more to share but I do know the SHOs are interested in being looped in. Thanks for including my team in these upcoming discussions and for all of your outreach. I've never met Paul — just an admirer from afar :). I'm here to help and and really grateful for all your are doing.
My best,
Rochelle

[Get Outlook for iOS](#)

From: Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>
Sent: Tuesday, May 25, 2021 7:07:45 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>
Subject: Meeting with Pediatric Cardiologists

Rochelle, Good evening. I met with pediatric cardiologists from the American Academy of Pediatrics. They confirmed what we have been discussing in regards to the cases of myocarditis. The cases are infrequent and mild and seem to resolve without treatment. We discussed their thoughts about the evaluation process with noninvasive studies. They will check on the experiences of others in the field throughout the county. I am arranging a meeting with them including your staff from the CDC and staff from the FDA this week.

In addition, I have a call with Paul Offit from CHOP tomorrow to gather his thoughts.

I was on a call with Bechara and the state and local health officials today as well. They articulated that they would appreciate an update if an official announcement would be forthcoming from the CDC about the cases.

Please let me know your thoughts.
Take care, Rachel

Rachel L. Levine, M.D.

Assistant Secretary for Health
Office of the Assistant Secretary for Health

Email: rachel.levine@hhs.gov
hhs.gov/ash

From: Walke, Henry (CDC/DDID/NCEZID/DPEI)
Sent: Thu, 13 May 2021 22:31:24 +0000
To: Berger, Sherri (CDC/OCOO/OD)
Cc: Schuchat, Anne MD (CDC/OD); Walensky, Rochelle (CDC/OD)
Subject: Re: Flagging: Agenda: Meeting on India with the Secretary (5/14/2021)

Will make sure we have good india bullets. (b)(5)
will have an update later tonight or am.

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 13, 2021 6:23:19 PM
To: Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: Flagging: Agenda: Meeting on India with the Secretary (5/14/2021)

Hi Henry – I know you will have the Epi in the daily update, anything else you've heard about that RW should plan to cover? Thanks

From: O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Sent: Thursday, May 13, 2021 5:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Woodcock, Janet (FDA/CDER) <Janet.Woodcock@fda.hhs.gov>; Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>; Smith, Marcella N. EOP/OSTP (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Levine, Rachel (HHS/OASH) <Rachel.Levine@hhs.gov>; Pace, Loyce (HHS/OS/OGA) <Loyce.Pace@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; XB78 (OS/IOS) <XB78@hhs.gov>
Cc: Mccluskie, Sean (HHS/IOS) <Sean.Mccluskie@hhs.gov>; Barclay, Lisa (HHS/OGC) <Lisa.Barclay@hhs.gov>; Lovenheim, Sarah (HHS/ASPA) <Sarah.Lovenheim@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Tierney, Julia (FDA/CBER) <Julia.Tierney@fda.hhs.gov>; Boateng, Sarah (HHS/OASH) <Sarah.Boateng@hhs.gov>; Lesko, Max (HHS/OASH) <Max.Lesko@hhs.gov>; Perry, Sherice (OS/IEA) <Sherice.Perry@hhs.gov>; Espinosa, Kimberly (HHS/ASL) <Kimberly.Espinosa@hhs.gov>
Subject: Agenda: Meeting on India with the Secretary (5/14/2021)

Dear all—we'll use our 10am meeting tomorrow to catch up on India and anything that we need to be tracking there. If there is additional time we might use it to discuss today's announcement on masking.

Proposed Agenda for tomorrow's meeting:

(b)(5)

(b)(5)

From: Sams, Ian (HHS/ASPA)
Sent: Tue, 27 Apr 2021 13:58:22 +0000
To: Walensky, Rochelle (CDC/OD)
Subject: myocarditis - here is what CDC/FDA responses are right now

Will try to track DOD update after their meeting...

Here is FDA response to media on myocarditis:

To date, FDA and CDC have not seen any new safety signals for myocarditis following administration of any of the authorized COVID-19 vaccines. Post-authorization safety monitoring during the COVID-19 pandemic vaccination program will aim to continuously monitor the safety of COVID-19 vaccines to rapidly detect safety problems if they exist. Should any new safety signals be identified by FDA and CDC through this safety surveillance, that information will be communicated to the public.

And CDC:

After 220 million doses of mRNA COVID-19 vaccine doses administered nationwide and over 5 million doses administered in the Vaccine Safety Datalink, CDC has not detected any indication of a safety problem with myocarditis or pericarditis. At this point there is no safety signal for myocarditis or pericarditis for COVID-19 vaccines in U.S. monitoring systems.

Myocarditis/pericarditis is an adverse event of special interest for U.S. vaccine safety surveillance of COVID-19 vaccines and is being closely monitored in the Vaccine Adverse Event Reporting System (VAERS) and in CDC's Vaccine Safety Datalink (VSD). CDC will continue to closely monitor the safety of COVID-19 vaccines for myocarditis/pericarditis and other adverse events.

--

Ian Sams

Deputy Assistant Secretary for Public Affairs (COVID Response)
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services
(202) 740-7169
ian.sams@hhs.gov

From: Beach, Michael J. (CDC/DDID/NCEZID/DFWED)
Sent: Wed, 3 Mar 2021 01:56:18 +0000
To: Pearlman, Aj (HHS/IOS); Sams, Ian (HHS/ASPA)
Cc: Berger, Sherri (CDC/OCOO/OD); Despres, Sarah (HHS/IOS); Jones, Christopher M. (CDC/DDNID/NCIPC/OD); Romanik, Nikki Jo (CDC/OD/OCS); Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS); Christie, Athalia (CDC/DDPHSIS/CGH/OD)
Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

thanks

Michael J. Beach, PhD
Principal Deputy Incident Manager
CDC COVID-19 Emergency Response
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329-4018
404-667-0718

From: Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>
Sent: Tuesday, March 2, 2021 8:51 PM
To: Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Romanik, Nikki Jo (CDC/OD/OCS) <kon6@cdc.gov>; Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS) <jpx1@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>
Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Thanks, Michael. Based on Sherri's note, it sounds like this should be in a holding pattern for now; Sarah and I will discuss and then come back to this group.

Thanks,
AJ

From: Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>
Sent: Tuesday, March 2, 2021 8:49 PM
To: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; fjr0 <fjr0@cdc.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Romanik, Nikki Jo (CDC/OD/OCS) <kon6@cdc.gov>; Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS) <jpx1@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

(b)(5)

Michael

Michael J. Beach, PhD
Principal Deputy Incident Manager
CDC COVID-19 Emergency Response
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329-4018
404-667-0718

From: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Sent: Tuesday, March 2, 2021 8:41 PM
To: Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJRO@cdc.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Romanik, Nikki Jo (CDC/OD/OCS) <kon6@cdc.gov>; Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS) <jpx1@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>
Subject: Re: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

I have not yet heard about the new Sail Order update - what's the upshot?

Sent from my iPhone

On Mar 2, 2021, at 8:36 PM, Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov> wrote:

FYI.

Just a note since I just heard a date for a new publication below. We also have the Conditional Sail Order Phase 2A finishing clearance----I think HHS is pretty familiar with this plan and its journey through OMB and the Department. Are we OK to post it when ready?

Thanks
Michael

(b)(5)

(b)(5)

(b)(5)

Michael J. Beach, PhD
Principal Deputy Incident Manager
CDC COVID-19 Emergency Response
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329-4018
404-667-0718

From: Berger, Sherri (CDC/OCOO/OD)
Sent: Wed, 3 Mar 2021 19:08:01 +0000
To: Williams, Ian (CDC/DDPHSIS/CPR/OD)
Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Nope sorry other Ian

From: Williams, Ian (CDC/DDPHSIS/CPR/OD) <iaw3@cdc.gov>
Sent: Wednesday, March 3, 2021 2:05 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Checking that you meant this for me...

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, March 3, 2021 1:53 PM
To: Espinosa, Kimberly (HHS/ASL) <Kimberly.Espinosa@hhs.gov>
Cc: Williams, Ian (CDC/DDPHSIS/CPR/OD) <iaw3@cdc.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>
Subject: FW: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Per chat

From: Berger, Sherri (CDC/OCOO/OD)
Sent: Tuesday, March 2, 2021 8:48 PM
To: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>
Cc: Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Romanik, Nikki Jo (CDC/OD/OCS) <kon6@cdc.gov>; Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS) <jpx1@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>
Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Jumping in... This was supposed to be discussed at the Principal's on Monday, but they did not get to it.

From: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Sent: Tuesday, March 2, 2021 8:41 PM
To: Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Pearlman,

Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Romanik, Nikki Jo (CDC/OD/OCS) <kon6@cdc.gov>; Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS) <jpx1@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>

Subject: Re: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

I have not yet heard about the new Sail Order update - what's the upshot?

Sent from my iPhone

On Mar 2, 2021, at 8:36 PM, Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov> wrote:

FYI.

Just a note since I just heard a date for a new publication below. We also have the Conditional Sail Order Phase 2A finishing clearance----I think HHS is pretty familiar with this plan and its journey through OMB and the Department. Are we OK to post it when ready?

Thanks
Michael

(b)(5)

(b)(5)

Michael J. Beach, PhD
Principal Deputy Incident Manager
CDC COVID-19 Emergency Response
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329-4018
404-667-0718

From: Berger, Sherri (CDC/OCOO/OD)
Sent: Wed, 3 Mar 2021 19:08:26 +0000
To: Espinosa, Kimberly (HHS/ASL)
Cc: Sams, Ian (HHS/ASPA); Pearlman, Aj (HHS/IOS)
Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Wrong Ian – now corrected

From: Berger, Sherri (CDC/OCOO/OD)
Sent: Wednesday, March 3, 2021 1:53 PM
To: Espinosa, Kimberly (HHS/ASL) <Kimberly.Espinosa@hhs.gov>
Cc: Ian Williams (CDC/DDPHSIS/CPR/OD) (iaw3@cdc.gov) <iaw3@cdc.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>
Subject: FW: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Per chat

From: Berger, Sherri (CDC/OCOO/OD)
Sent: Tuesday, March 2, 2021 8:48 PM
To: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>
Cc: Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Romanik, Nikki Jo (CDC/OD/OCS) <kon6@cdc.gov>; Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS) <jpx1@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>
Subject: RE: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

Jumping in... This was supposed to be discussed at the Principal's on Monday, but they did not get to it.

From: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>
Sent: Tuesday, March 2, 2021 8:41 PM
To: Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Pearlman, Aj (HHS/IOS) <Aj.Pearlman@hhs.gov>; Romanik, Nikki Jo (CDC/OD/OCS) <kon6@cdc.gov>; Marandet, Angele G. (CDC/DDID/NCHHSTP/DHPIRS) <jpx1@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>
Subject: Re: COVID-19: CDC/HHS Product Awareness (Not for S/R)---new publication tomorrow and question on Conditional Sail Order Phase 2A

I have not yet heard about the new Sail Order update - what's the upshot?

Sent from my iPhone

On Mar 2, 2021, at 8:36 PM, Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov> wrote:

FYI.

Just a note since I just heard a date for a new publication below. We also have the Conditional Sail Order Phase 2A finishing clearance----I think HHS is pretty familiar with this plan and its journey through OMB and the Department. Are we OK to post it when ready?

Thanks

Michael

(b)(5)



Others mentioned before for this week

(b)(5)



(b)(5)

Michael J. Beach, PhD
Principal Deputy Incident Manager
CDC COVID-19 Emergency Response
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329-4018
404-667-0718

From: Schuchat, Anne MD (CDC/OD)
Sent: Mon, 24 May 2021 00:19:41 +0000
To: Despres, Sarah (HHS/IOS); Berger, Sherri (CDC/OCOO/OD); Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)
Cc: Sams, Ian (HHS/ASPA); O'Connell, Dawn (HHS/IOS); Cha, Stephen (HHS/IOS)
Subject: Re: HAN on myocarditis

It won't be tomorrow. Still working things through.

Get [Outlook for iOS](#)

From: Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>
Sent: Sunday, May 23, 2021 8:17:43 PM
To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Cc: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>; Cha, Stephen (HHS/IOS) <Stephen.Cha@hhs.gov>
Subject: RE: HAN on myocarditis

Thank you.

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Sunday, May 23, 2021 4:37 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>
Cc: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>; Cha, Stephen (HHS/IOS) <Stephen.Cha@hhs.gov>
Subject: RE: HAN on myocarditis

Will follow up but believe aim was for early this week. Just targeting Emergency departments rather than broad advisory.

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Sunday, May 23, 2021 4:33 PM
To: Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Cc: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>; Cha, Stephen (HHS/IOS) <Stephen.Cha@hhs.gov>
Subject: RE: HAN on myocarditis

+Abbigail & Anne to respond, thanks

From: Despres, Sarah (HHS/IOS) <Sarah.Despres@hhs.gov>
Sent: Sunday, May 23, 2021 3:29 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Cc: Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; O'Connell, Dawn (HHS/IOS)

<Dawn.Oconnell@hhs.gov>; Cha, Stephen (HHS/IOS) <Stephen.Cha@hhs.gov>

Subject: HAN on myocarditis

Sherri,

We just got a heads up from FDA that CDC is issuing a HAN on myocarditis/mRNA vaccines. I know that Ian is already looped in but if you could make sure we see the HAN when it goes that would be great. Would also love to know timing.

Thanks.

From: O'Connell, Dawn (HHS/IOS)
Sent: Mon, 24 May 2021 12:59:41 +0000
To: Berger, Sherri (CDC/OCOO/OD)
Cc: Walensky, Rochelle (CDC/OD)
Subject: RE: Today's 130PM

Great, thanks so much!

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Monday, May 24, 2021 8:51 AM
To: O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: Today's 130PM

RW will plan to also cover myocarditis. Thanks

Sherri A. Berger, MSPH
Chief of Staff (acting)
Centers for Disease Control and Prevention
SBerger@cdc.gov
404.213.8392 cell
404.639.7846 desk

From: Berger, Sherri (CDC/OCOO/OD)
Sent: Thu, 27 May 2021 14:31:58 +0000
To: O'Connell, Dawn (HHS/IOS)
Cc: Walensky, Rochelle (CDC/OD)
Subject: RE: Myocarditis plan - Heads up?

Hi Dawn –

I just learned that Abbigail told Courtney.

Do we need another connection before we move forward? You have the materials in your inbox.

Thanks

From: O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Sent: Thursday, May 27, 2021 10:27 AM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Cc: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: Myocarditis plan - Heads up?

I haven't. Still tangled in summer camps. What's timeline? The 3 of us should all talk v. soon about how to move things forward.

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, May 27, 2021 10:23 AM
To: O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>
Cc: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: Myocarditis plan - Heads up?
Importance: High

(b)(5)

Thanks